The effect of SGLT-2 inhibitors on liver stiffness in patients with diabetes mellitus and heart failure: a Fibroscan study.

IF 1.6 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Irish Journal of Medical Science Pub Date : 2025-09-13 DOI:10.1007/s11845-025-04087-z

Huseyin Ali Ozturk, Hilmi Erdem Sumbul

{"title":"The effect of SGLT-2 inhibitors on liver stiffness in patients with diabetes mellitus and heart failure: a Fibroscan study.","authors":"Huseyin Ali Ozturk, Hilmi Erdem Sumbul","doi":"10.1007/s11845-025-04087-z","DOIUrl":null,"url":null,"abstract":"Aim: Studies have shown an increase in liver stiffness (LS) by liver elastography in patients with type 2 diabetes mellitus (DM) and regression of LS in patients receiving SGLT-2 inhibitors (SGLT-2i). We aimed to investigate liver stiffness and related factors before and after treatment with SGLT-2i in patients with diabetes and heart failure.Methods: In our prospective and cross-sectional study, 237 patients with diabetes were included. Patients were divided into 3 groups according to the presence and status of heart failure. Patients were treated with SGLT-2i, and their pre- and post-treatment status was evaluated. LS measurements were performed with FibroScan® Mini 430 device (Echosens, France).Results: NT-proBNP levels decreased significantly in all groups, with the most pronounced reduction in the HFrEF group (p < 0.001). Liver stiffness (kPa) also improved significantly in all groups, with the greatest change observed in the HFrEF group (Δ = 2.11 ± 1.1 kPa, p < 0.001). Similarly, HbA1c levels showed marked reductions across all groups, with the highest improvement seen in the group without heart failure (Δ = 1.28 ± 0.63%, p < 0.001).Conclusion: Our findings reinforce the potential of SGLT-2i therapy to improve liver stiffness and related metabolic and cardiac parameters in diabetic patients, irrespective of heart failure status.","PeriodicalId":14507,"journal":{"name":"Irish Journal of Medical Science","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Irish Journal of Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11845-025-04087-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Studies have shown an increase in liver stiffness (LS) by liver elastography in patients with type 2 diabetes mellitus (DM) and regression of LS in patients receiving SGLT-2 inhibitors (SGLT-2i). We aimed to investigate liver stiffness and related factors before and after treatment with SGLT-2i in patients with diabetes and heart failure.

Methods: In our prospective and cross-sectional study, 237 patients with diabetes were included. Patients were divided into 3 groups according to the presence and status of heart failure. Patients were treated with SGLT-2i, and their pre- and post-treatment status was evaluated. LS measurements were performed with FibroScan® Mini 430 device (Echosens, France).

Results: NT-proBNP levels decreased significantly in all groups, with the most pronounced reduction in the HFrEF group (p < 0.001). Liver stiffness (kPa) also improved significantly in all groups, with the greatest change observed in the HFrEF group (Δ = 2.11 ± 1.1 kPa, p < 0.001). Similarly, HbA1c levels showed marked reductions across all groups, with the highest improvement seen in the group without heart failure (Δ = 1.28 ± 0.63%, p < 0.001).

Conclusion: Our findings reinforce the potential of SGLT-2i therapy to improve liver stiffness and related metabolic and cardiac parameters in diabetic patients, irrespective of heart failure status.

查看原文本刊更多论文

SGLT-2抑制剂对糖尿病和心力衰竭患者肝僵硬的影响：一项纤维扫描研究

目的：研究表明，2型糖尿病（DM）患者肝弹性成像显示肝硬度（LS）增加，接受SGLT-2抑制剂（SGLT-2i）治疗的患者肝硬度（LS）下降。我们的目的是研究SGLT-2i治疗糖尿病和心力衰竭患者前后肝脏僵硬及相关因素。方法：在我们的前瞻性和横断面研究中，纳入了237例糖尿病患者。根据心衰的存在及状态将患者分为3组。患者接受SGLT-2i治疗，并评估其治疗前和治疗后状态。LS测量采用FibroScan®Mini 430设备（Echosens，法国）。结果：NT-proBNP水平在所有组中均显著下降，其中以HFrEF组下降最为明显(p)。结论：我们的研究结果强化了SGLT-2i治疗改善糖尿病患者肝僵硬度及相关代谢和心脏参数的潜力，而与心力衰竭状态无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Irish Journal of Medical Science 医学-医学：内科

CiteScore

3.70

自引率

4.80%

发文量

357

审稿时长

4-8 weeks

期刊介绍： The Irish Journal of Medical Science is the official organ of the Royal Academy of Medicine in Ireland. Established in 1832, this quarterly journal is a contribution to medical science and an ideal forum for the younger medical/scientific professional to enter world literature and an ideal launching platform now, as in the past, for many a young research worker. The primary role of both the Academy and IJMS is that of providing a forum for the exchange of scientific information and to promote academic discussion, so essential to scientific progress.